←
Simanshu Dhirendra185 posts
Simanshu Dhirendra avatar

Simanshu Dhirendra

@simanshu

Group lead (Structural Biology) at NCI RAS Initiative @FredNatLab; RAS/RAF/PI3K structural biology and drug discovery

◷ Joined April 2009▧ 12 Photos and videos
Simanshu Dhirendra avatar
Simanshu Dhirendra@simanshu·Apr 22

In this review, we revisit this framework and propose that RAS family members exhibit intrinsic effector preferences, pointing to a more specialized and organized signaling network that reflects a more structured division of labor within the network.

Simanshu Dhirendra avatar
Simanshu Dhirendra@simanshu·Apr 22

Historically, the canonical RAS proteins—KRAS, HRAS, and NRAS—have been viewed as the primary drivers of signaling, with their GTP-bound forms assumed to uniformly activate all major downstream effector pathways at the plasma membrane. But is this model too simplistic?

Pau Castel avatar
⟳ Simanshu Dhirendra retweeted
Pau Castel@castel_pau·11 Sep 2025

Excited to share our latest work onll LZTR1 just published @ScienceMagazine!! A wonderful multidisciplinary collaboration between @simanshu's lab and our lab that provides structural understanding on RAS substrate and nucleotide specificity, and effect of mutations in LZTR1.

Simanshu Dhirendra avatar
Simanshu Dhirendra@simanshu·12 Jun 2025

BBO-10203 is currently being evaluated in the Phase 1 BREAKER-101 trial (NCT06625775) in patients with HER2+ and HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer.

Simanshu Dhirendra avatar
Simanshu Dhirendra@simanshu·12 Jun 2025

This publication describes how BBO-10203 disrupts the RAS–PI3Kα interaction without impairing insulin signaling, resulting in broad antitumor activity across multiple cancer models. It also shows enhanced efficacy in combination with other targeted agents.

Simanshu Dhirendra avatar
Simanshu Dhirendra@simanshu·12 Jun 2025

Our longstanding, cross-institutional journey from concept to clinic is powered by the dedication of many scientists from BridgeBio Oncology Therapeutics, Lawrence Livermore National Laboratory, and the NCI RAS Initiative at Frederick National Laboratory for Cancer Research.

Simanshu Dhirendra avatar
Simanshu Dhirendra@simanshu·12 Jun 2025

We are excited to share our collaborative work on the first-in-class RAS:PI3Kα breaker, BBO-10203, which has now been published online in @ScienceMagazine ! 🔗 Read the full article here: science.org/doi/10.1126/scie… BridgeBio Oncology Therapeutics (BBOT) @FredNatLab @Livermore_Lab

Simanshu Dhirendra avatar
Simanshu Dhirendra@simanshu·9 Jan 2025

This work was led by Daniel Czyzyk and Wupeng Yan in the laboratory, in collaboration with RAS Initiative colleagues and researchers at Daiichi Sankyo.

Simanshu Dhirendra avatar
Simanshu Dhirendra@simanshu·9 Jan 2025

Our findings reveal key interaction interfaces and isoform-specific differences in RAS-PI3Kα, highlighting its crucial role in activating the PI3K-AKT-mTOR pathway and providing a blueprint for designing isoform-specific inhibitors to target RAS- and PI3K-driven cancers.

Simanshu Dhirendra avatar
Simanshu Dhirendra@simanshu·9 Jan 2025

Mutations in RAS and PI3Kα are significant drivers of cancer, but the precise structural mechanisms governing their interaction have remained elusive—until now. Here, we reveal the detailed structures of KRAS, RRAS2, and MRAS in complex with the catalytic subunit of PI3Kα.

Simanshu Dhirendra avatar
Simanshu Dhirendra@simanshu·7 Dec 2024

Our structural-guided insights contributed to the design of BBO-8520, a first-in-class dual inhibitor targeting both GTP-bound (ON) and GDP-bound (OFF) KRAS G12C. Excited to see this work now published in @CD_AACR! @FredNatLab @BridgeBioPharma

Now online in @CD_AACR: Discovery of BBO-8520, a First-in-Class Direct & Covalent Dual Inhibitor of GTP-Bound (ON) & GDP-Bound (OFF) KRAS G12C - by Anna Maciag, James Stice, Bin Wang, @frankpmccormick, Pedro Beltran, et al. doi.org/10.1158/2159-8290.CD… @FredNatLab @BridgeBioPharma

Post attachment
AACR avatar
⟳ Simanshu Dhirendra retweeted
AACR@AACR·8 Apr 2024

The three-part New Drugs on the Horizon Series at the AACR Annual Meeting 2024 wrapped up this morning. A total of 12 first-time disclosures were presented. bit.ly/3J8AmVM #AACR24

Post attachment